Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.